Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Holdings
Ownership
Insiders





All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other

Tags
Inv. presentation
Acq. announced
Quarterly results

PTC THERAPEUTICS, INC. (PTCT) Create: Alert

All | News | Filings
Date FiledTypeDescription
09/28/2023 8-K Quarterly results
08/03/2023 8-K Quarterly results
07/19/2023 8-K Regulation FD Disclosure, Other Events, Financial Statements and Exhibits  Interactive Data
07/17/2023 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
06/06/2023 8-K Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits  Interactive Data
05/23/2023 8-K Cost Associated with Exit or Disposal Activities, Departure of Directors or Certain Officers; Election of Directors; Appointm...
Docs: "PTC Therapeutics Announces Strategic Pipeline Prioritization",
"PTC Therapeutics Announces Topline Results from Vatiquinone MOVE-FA Registration-Directed Trial",
"62 61 123 73 70 143"
05/17/2023 8-K Regulation FD Disclosure, Other Events, Financial Statements and Exhibits  Interactive Data
04/27/2023 8-K Quarterly results
04/18/2023 8-K Quarterly results
03/24/2023 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "Non-Disparagement. To the extent permitted by law, Executive understands and agrees that as a condition for payments and benefits under this Agreement, for a period of five years following the date hereof Executive shall not make any false, disparaging or derogatory statements to any person or entity, including any media outlet, regarding the Company or any of its directors, officers, employees, agents or representatives or about the Company’ s business affairs and financial condition. Executive further agrees that as a condition for payments and benefits under this Agreement any statements made by Executive regarding the Company shall be consistent in tenor, tone and content with the statements made in the press release filed by the Company on or around the date hereof announcing Executiv...",
"Stuart Peltz, Ph.D., Rare Disease Pioneer, to Retire as Chief Executive Officer of PTC Therapeutics"
01/09/2023 8-K Quarterly results
12/06/2022 8-K Quarterly results
10/27/2022 8-K Quarterly results
10/27/2022 8-K Quarterly results
10/18/2022 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
09/07/2022 8-K Investor presentation
08/15/2022 8-K Quarterly results
08/04/2022 8-K Quarterly results
06/21/2022 8-K Quarterly results
06/09/2022 8-K Quarterly results
05/27/2022 8-K Quarterly results
05/03/2022 8-K Quarterly results
02/22/2022 8-K Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits  I...
01/10/2022 8-K Results of Operations and Financial Condition, Departure of Directors or Certain Officers; Election of Directors; Appointment...
11/30/2021 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
10/28/2021 8-K Quarterly results
09/23/2021 8-K Quarterly results
07/29/2021 8-K Quarterly results
06/09/2021 8-K Quarterly results
05/04/2021 8-K Quarterly results
04/15/2021 8-K Quarterly results
02/25/2021 8-K Quarterly results
02/04/2021 8-K Quarterly results
01/11/2021 8-K Quarterly results
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy